- Home
- NERV vs GRNQ Comparison
NERV vs GRNQ Comparison
Compare NERV & GRNQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- GRNQ
- Stock Information
- Founded
- NERV 2007
- GRNQ 2013
- Country
- NERV United States
- GRNQ Malaysia
- Employees
- NERV N/A
- GRNQ N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- GRNQ EDP Services
- Sector
- NERV Health Care
- GRNQ Technology
- Exchange
- NERV Nasdaq
- GRNQ Nasdaq
- Market Cap
- NERV 12.6M
- GRNQ 13.3M
- IPO Year
- NERV 2014
- GRNQ 2018
- Fundamental
- Price
- NERV $1.77
- GRNQ $1.54
- Analyst Decision
- NERV Hold
- GRNQ
- Analyst Count
- NERV 1
- GRNQ 0
- Target Price
- NERV $5.00
- GRNQ N/A
- AVG Volume (30 Days)
- NERV 12.2K
- GRNQ 85.5K
- Earning Date
- NERV 08-05-2025
- GRNQ 08-12-2025
- Dividend Yield
- NERV N/A
- GRNQ N/A
- EPS Growth
- NERV N/A
- GRNQ N/A
- EPS
- NERV 0.83
- GRNQ N/A
- Revenue
- NERV N/A
- GRNQ $3,190,761.00
- Revenue This Year
- NERV N/A
- GRNQ N/A
- Revenue Next Year
- NERV N/A
- GRNQ N/A
- P/E Ratio
- NERV $2.18
- GRNQ N/A
- Revenue Growth
- NERV N/A
- GRNQ N/A
- 52 Week Low
- NERV $1.15
- GRNQ $0.80
- 52 Week High
- NERV $3.50
- GRNQ $2.24
- Technical
- Relative Strength Index (RSI)
- NERV 57.10
- GRNQ 56.94
- Support Level
- NERV $1.62
- GRNQ $1.47
- Resistance Level
- NERV $1.83
- GRNQ $1.70
- Average True Range (ATR)
- NERV 0.09
- GRNQ 0.18
- MACD
- NERV -0.00
- GRNQ -0.01
- Stochastic Oscillator
- NERV 64.29
- GRNQ 48.19
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About GRNQ Greenpro Capital Corp.
Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust and wealth management. Its segments include Service business engaged in the provision of corporate advisory and business solution services; Real estate business segment engaged in trading or leasing of commercial real estate properties in Hong Kong and Malaysia; and Digital business segment engaged in provision of digital platform and trading of digital assets.